KRAS-mutant non-small cell lung cancer (NSCLC) therapy based on tepotinib and omeprazole combination.
Por:
Rosell R, Jantus-Lewintre E, Cao P, Cai X, Xing B, Ito M, Gomez-Vazquez JL, Marco-Jordán M, Calabuig-Fariñas S, Cardona AF, Codony-Servat J, Gonzalez J, València-Clua K, Aguilar A, Pedraz-Valdunciel C, Dantes Z, Jain A, Chandan S, Molina-Vila MA, Arrieta O, Ferrero M, Camps C and González-Cao M
Publicada:
12 jun 2024
Resumen:
KRAS-mutant non-small cell lung cancer (NSCLC) shows a relatively low response rate to chemotherapy, immunotherapy and KRAS-G12C selective inhibitors, leading to short median progression-free survival, and overall survival. The MET receptor tyrosine kinase (c-MET), the cognate receptor of hepatocyte growth factor (HGF), was reported to be overexpressed in KRAS-mutant lung cancer cells leading to tumor-growth in anchorage-independent conditions.
Filiaciones:
Rosell R:
Germans Trias i Pujol Research Institute, Badalona (IGTP), Barcelona, Spain.
IOR, Hospital Quiron-Dexeus Barcelona, Barcelona, Spain.
Laboratory of Molecular Biology, Germans Trias i Pujol Health Sciences Institute and Hospital (IGTP), Camí de les Escoles, s/n, 08916, Badalona, Barcelona, Spain.
Jantus-Lewintre E:
Molecular Oncology Laboratory, Fundación Investigación Hospital General Universitario de Valencia, Valencia, Spain.
Trial Mixed Unit, Centro Investigación Príncipe Felipe-Fundación Investigación Hospital General Universitario de Valencia, Valencia, Spain.
Centro de Investigación Biomédica en Red de Cáncer, CIBERONC, Madrid, Spain.
Department of Biotechnology, Universitat Politècnica de València, Camí de Vera s/n, Valencia, 46022, Spain.
Joint Unit: Nanomedicine, Centro Investigación Príncipe Felipe-Universitat Politècnica de Valencia, Valencia, Spain.
Cao P:
Jiangsu Provincial Medical Innovation Center, Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, China.
State Key Laboratory on Technologies for Chinese Medicine Pharmaceutical Process Control and Intelligent Manufacture, Nanjing University of Chinese Medicine, Nanjing, China.
The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou Peoples Hospital, Quzhou, China.
Shandong Academy of Chinese Medicine, Jinan, China.
Cai X:
Jiangsu Provincial Medical Innovation Center, Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, China
Xing B:
Jiangsu Provincial Medical Innovation Center, Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, China
Ito M:
Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan
Gomez-Vazquez JL:
Germans Trias i Pujol Research Institute, Badalona (IGTP), Barcelona, Spain
Hospital Universitari de Bellvitge, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain
Marco-Jordán M:
Germans Trias i Pujol Research Institute, Badalona (IGTP), Barcelona, Spain
Calabuig-Fariñas S:
Molecular Oncology Laboratory, Fundación Investigación Hospital General Universitario de Valencia, Valencia, Spain
TRIAL Mixed Unit, Centro Investigación Príncipe Felipe-Fundación Investigación Hospital General Universitario de Valencia, Valencia, Spain
Centro de Investigación Biomédica en Red de Cáncer, CIBERONC, Madrid, Spain
Department of Pathology, Universitat de València, Valencia, Spain
Cardona AF:
Institute of Research and Education, Luis Carlos Sarmiento Angulo Cancer Treatment and Research Center - CTIC, Bogotá, Colombia
Codony-Servat J:
Germans Trias i Pujol Research Institute, Badalona (IGTP), Barcelona, Spain
Pangaea Oncology, Hospital Quiron-Dexeus Barcelona, Barcelona, Spain
Gonzalez J:
Germans Trias i Pujol Research Institute, Badalona (IGTP), Barcelona, Spain
València-Clua K:
Germans Trias i Pujol Research Institute, Badalona (IGTP), Barcelona, Spain
Aguilar A:
IOR, Hospital Quiron-Dexeus Barcelona, Barcelona, Spain
Pedraz-Valdunciel C:
Invitrocue, Barcelona, Spain
Dantes Z:
Invitrocue, Munich, Germany
Jain A:
Department of Microbiology, JSS Academy of Higher Education & Research, Mysuru, India
Chandan S:
Department of Microbiology, JSS Academy of Higher Education & Research, Mysuru, India
Molina-Vila MA:
Pangaea Oncology, Hospital Quiron-Dexeus Barcelona, Barcelona, Spain
Arrieta O:
National Institute of Cancerology (INCAN), Mexico City, Mexico
Ferrero M:
TRIAL Mixed Unit, Centro Investigación Príncipe Felipe-Fundación Investigación Hospital General Universitario de Valencia, Valencia, Spain
Centro de Investigación Biomédica en Red de Cáncer, CIBERONC, Madrid, Spain
:
TRIAL Mixed Unit, Centro Investigación Príncipe Felipe-Fundación Investigación Hospital General Universitario de Valencia, Valencia, Spain
Centro de Investigación Biomédica en Red de Cáncer, CIBERONC, Madrid, Spain
Medical Oncology Department, General University Hospital of Valencia, Valencia, Spain
González-Cao M:
IOR, Hospital Quiron-Dexeus Barcelona, Barcelona, Spain
Green Published, gold
|